How Is CMML Different From CML, MDS and Other Blood Cancers?

When you are diagnosed with a blood cancer, hearing terms like “myeloid,” “myelomonocytic,” and “myelodysplastic” can be incredibly confusing. The short answer to how chronic myelomonocytic leukemia (CMML) differs from other blood cancers is that CMML is defined by a specific combination of features: a persistent overproduction of monocytes (a type of white blood cell), abnormal bone marrow cells, and acquired genetic changes ^[1].

In contrast, classic chronic myeloid leukemia (CML) is driven by a distinct genetic mutation, while myelodysplastic syndromes (MDS) and other overlapping diseases feature different abnormal cell patterns ^[2][3]. Understanding exactly which condition you have is critical because the treatments, disease behaviors, and long-term outlooks for each are very different ^[4].

How Doctors Confirm CMML

Diagnosing CMML requires a careful workup to rule out other causes of high monocytes (such as infections) and to distinguish it from similar blood cancers. Doctors look for three main criteria:

1. Persistent Monocytosis: An absolute monocyte count of at least 0.5 × 10⁹/L, with monocytes making up at least 10% of your total white blood cells, lasting for at least three months ^[1]. A high count alone is not enough to make a diagnosis.
2. Bone Marrow Dysplasia and/or Clonality: Cells must look abnormal under a microscope (dysplasia), or genetic testing must show mutations (like TET2, SRSF2, or ASXL1) proving the cells share an acquired abnormal change, known as clonality ^[1].
3. Exclusion of Other Conditions: The care team must confirm you do not have classic CML, a prior history of a myeloproliferative neoplasm, or specific rare gene rearrangements ^[2][5].

CMML vs. Chronic Myeloid Leukemia (CML)

Despite their similar names, CMML and CML are distinct diseases. The most important difference is a specific genetic mutation called the Philadelphia chromosome or the BCR::ABL1 fusion gene ^[2].

• CML is defined by the presence of this BCR::ABL1 mutation ^[2]. It typically causes an overproduction of granulocytes (another type of white blood cell). Because the exact genetic cause is known, CML is highly treatable with targeted oral medications called tyrosine kinase inhibitors (TKIs).
• CMML does not have the BCR::ABL1 mutation ^[2]. Because it lacks this specific genetic target, CMML is not treated with standard BCR::ABL1-directed CML therapy ^[2]. Instead, it is characterized by monocytosis and other genetic mutations ^[1].

CMML vs. Myelodysplastic Syndromes (MDS)

MDS and CMML share several features. CMML is considered an “overlap” disease that has both myelodysplastic (poorly formed cells) and myeloproliferative (overproduced cells) traits.

• MDS primarily involves dysplasia—bone marrow cells that do not mature properly. While MDS often leads to low blood counts (cytopenias), counts can sometimes be normal or high ^[6].
• CMML also features dysplasia and can cause low red blood cells or platelets, but it is set apart by its defining requirement of monocytosis ^[1].

Recent diagnostic guidelines lowered the monocyte threshold required for a CMML diagnosis ^[1]. As a result, some patients who might have been classified as having MDS in the past may now meet the criteria for CMML, provided all other diagnostic requirements are met ^[6].

CMML vs. Atypical CML and MPNs

Other rare blood cancers can mimic CMML, but they overproduce different cells or have different genetic drivers.

• MDS/MPN with Neutrophilia (formerly atypical CML or aCML): This rare disease involves a high number of neutrophils (another type of white blood cell), circulating immature myeloid cells, and abnormal cell development, but lacks the high monocyte count seen in CMML ^[3][7].
• Myeloproliferative Neoplasms (MPNs): Diseases like polycythemia vera (PV) or essential thrombocythemia (ET) cause the body to make too many red blood cells or platelets. If a patient has a documented history of an MPN, a new diagnosis of CMML is generally excluded ^[5].
• Rare Gene Rearrangements: Occasionally, a patient might have a rare cancer driven by specific gene rearrangements (such as PDGFRA or PDGFRB). These can cause high monocytes and high eosinophils, mimicking CMML, but they require entirely different targeted treatments ^[8][9].

Quick Comparison

The Blast Limit

Across these blood cancers, doctors closely monitor the percentage of blasts (immature precursor cells) in your blood and bone marrow. Blasts are not automatically malignant in every context, but their numbers help determine disease severity.

For CMML, reaching 20% blasts in the blood or marrow generally indicates the disease has transformed into Acute Myeloid Leukemia (AML) ^[1]. CMML is not just “early AML,” but there is a risk it can progress over time ^[10]. It is important to note that CML blast phase and modern AML/MDS classifications have different criteria, and AML can sometimes be diagnosed below 20% if specific genetic abnormalities are present ^[1].

Why the Exact Diagnosis Matters

Because these diseases are driven by different biological mechanisms, they require individualized management strategies. CMML itself is often divided into dysplastic (lower white blood cell count) and proliferative (higher white blood cell count) subtypes, which behave differently and influence your risk score ^[10].

Your hematologist may use a combination of blood tests, bone marrow biopsies, and advanced genetic sequencing to rule out other diseases, support evidence of clonality, and assess your individual risk ^[1][9]. CMML treatments may involve observation, symptom management, hypomethylating agents, or clinical trials. For selected patients with higher-risk disease who are medically fit, an allogeneic (donor) stem cell transplant may be discussed. While a transplant is the only established potentially curative approach, it carries substantial risks and is not appropriate for everyone ^[4].